Tetrabenazine Dosing for Tardive Dyskinesia
Start tetrabenazine at 12.5 mg once daily in the morning, then increase by 12.5 mg weekly to a target of 25-50 mg/day divided into 2-3 doses, with a maximum of 50 mg/day (25 mg single dose) unless CYP2D6 genotyping confirms extensive metabolizer status. 1
Initial Dosing Strategy
The FDA-approved dosing protocol for tetrabenazine, while established for Huntington's disease chorea, provides the framework for TD treatment given the APA's strong recommendation (1B) to use VMAT2 inhibitors for moderate to severe tardive dyskinesia 2:
- Week 1: 12.5 mg once daily (morning)
- Week 2: 12.5 mg twice daily (25 mg/day total)
- Week 3+: Increase by 12.5 mg/day weekly as tolerated 1
Divide doses into 2-3 times daily once exceeding 25 mg/day. The maximum single dose should not exceed 25 mg 1.
Critical Dosing Threshold: The 50 mg/day Decision Point
If you need more than 50 mg/day, you MUST obtain CYP2D6 genotyping before proceeding 1. This is non-negotiable because:
For Extensive/Intermediate Metabolizers (EMs/IMs):
- Continue weekly titration by 12.5 mg/day
- Maximum daily dose: 100 mg/day
- Maximum single dose: 37.5 mg
- Divide into three times daily dosing 1
For Poor Metabolizers (PMs):
- STOP at 50 mg/day maximum
- Maximum single dose remains 25 mg
- Higher doses cause excessive drug accumulation 1
Dose Adjustments for Drug Interactions
If the patient takes strong CYP2D6 inhibitors (quinidine, paroxetine, fluoxetine, bupropion):
- Treat them as a poor metabolizer
- Maximum dose: 50 mg/day
- Maximum single dose: 25 mg 1
Evidence-Based Efficacy in TD
Research demonstrates tetrabenazine's effectiveness specifically for TD at mean doses of 57.9 mg/day (range not specified, but achieved after mean 20.3 weeks of titration) 3. In this randomized videotape protocol study, 19 of 20 patients showed significant improvement on blinded AIMS ratings and continued treatment long-term 3. Another series reported successful treatment of 23 TD cases with tetrabenazine 4.
Older data from 44 TD patients showed a mean response rating of 2.3 on a 0-5 scale (where 1=marked improvement) at approximately 18 months follow-up 5.
Managing Adverse Effects During Titration
Stop titration immediately if these occur 1:
- Akathisia or restlessness
- Parkinsonism
- Depression or suicidality
- Severe sedation
- Insomnia or anxiety
Then reduce the dose. If symptoms persist, either discontinue tetrabenazine or initiate specific treatment (e.g., antidepressants for depression) 1.
Common Adverse Effects from TD Studies:
- Parkinsonism (most common)
- Sedation (caused one dropout in the randomized trial) 3
- Depression
- Akathisia 5
Critical Safety Warnings
Tetrabenazine is CONTRAINDICATED in 1:
- Actively suicidal patients
- Untreated or inadequately treated depression
Black Box Warning: Tetrabenazine increases risk of depression and suicidality. Close monitoring is mandatory, especially in patients with prior depression or suicide attempts 1.
Practical Titration Timeline
For most TD patients without CYP2D6 testing:
- Weeks 1-4: Reach 37.5-50 mg/day (the safe maximum without genotyping)
- Assess response at Week 4-8: Research shows mean treatment duration of 20 weeks before optimal benefit 3
- If inadequate response at 50 mg/day: Order CYP2D6 genotyping before increasing further
Hepatic Impairment Considerations
While the FDA label for tetrabenazine does not provide specific hepatic dosing adjustments in the provided excerpts, the drug undergoes extensive hepatic metabolism with very low bioavailability (F=0.06) and clearance approaching hepatic blood flow 6. Exercise caution and use lower doses in hepatic impairment, though specific guidelines are not established in the available evidence.
Administration
Tetrabenazine can be taken without regard to food 1. For patients unable to swallow (though this is more relevant for deutetrabenazine, a related compound), crushing may be considered in severe cases 7.